comprehensive -WSS

comprehensive

author：explore 2025-10-01 20:15:36 - browse：227

3D dollar signs come out of a prescription drug bottle — coverage from STAT — Adobe

WASHINGTON — Venture capitalists are still pouring money into drug research in spite of Medicare’s new power to negotiate drug prices, according to Congress’ nonpartisan budget experts.

The Inflation Reduction Act includes two measures that directly lower drug prices. Medicare price negotiation is the most controversial of the two. The law gives drugs 9 years on the market before negotiated prices take effect; biologics get 13 years. Drugs are selected for negotiation among the 50 top-selling drugs without generic or biosimilar competition. Medicare will negotiate prices for 10 drugs to start. Up to 60 drugs will be subject to negotiation over the next four years, and up to 20 more drugs every year afterward.

The law also requires drug companies to pay back Medicare when they raise prices on drugs faster than inflation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： STAT Boddities: What happens to the brain when we get scared?

focus

leisure time

WSS

WATCH: Why do bright lights make us see spots?

Congress considering partial increase for doctor pay in Medicare

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Why Eli Lilly’s earnings didn’t quite live up to the hype

Generate Biomedicines machine learning biotech raises $273M

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

hotspot

comprehensive

hotspot

ChatGPT in medicine: STAT answers readers' burning questions

How housing is health care on Long Island

Moonlake's readout produced a cash windfall. Risks remain

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Supreme Court strikes down use of affirmative action

Food makers tried to stack nutrition panel with preferred experts

The high cost of giving birth even with insurance

Telehealth for opioid use disorder is lifesaving

The cancer drug shortage isn’t new — and neither are the solutions

How housing is health care on Long Island

Wikipedia

Diverse clinical trials: Why aren’t we there yet?

Report cites 'urgent' need to recruit more diverse clinical trial participants

Why Eli Lilly’s earnings didn’t quite live up to the hype

FDA proposes changes to key medical devices approval pathway

IRA could hurt research into orphan drugs for rare diseases

Here’s what’s in the FDA plan to include pregnant women in clinical trials

knowledge

focus

leisure time

hotspot